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Abstract
: Post-stroke fatigue (PSF) is one of the most common andBackground
frustrating outcomes of stroke. It has a high prevalence and it can persist for
many years after stroke. PSF itself contributes to a wider range of
undesirable outcomes that affect all aspects of daily life. The aim of this
review was to identify and summarise the most recent research on PSF, in
order to update the evidence base.
: We updated an existing review (Hinkle  . 2017)Methods et al
systematically searching CINAHL, MEDLINE, PsycINFO, and PubMed to
cover new research studies between 1  March 2016 and the search date
(19  January 2020). We included interventional and observational
research, and clinical practice guidelines that were not covered in the
original review. After duplicate removal in EndNote, two reviewers screened
the search results in Rayyan, and data from eligible full texts were extracted
onto an Excel spreadsheet. Finally, we used RobotReviewer and a human
reviewer to assess the risk of bias of randomised trials for this scoping
review.
: We identified 45 records for 30 studies (14 observational, 10Results
interventional studies, and 6 guidelines). Apart from one, the interventional
studies were single-centred, had high risk of bias and small sample size
(median 50). They investigated exercise, pharmacotherapy,
psychotherapy, education, and light therapy. Observational studies mainly
reported the factors related to PSF including co-morbidities, depression
and anxiety, quality of life, activities of daily living, stroke severity,
medication use and polypharmacy, polymorphism, pain, apathy, limb
heaviness, neuroticism, mobility, and thyroid-stimulating hormone.
Guidelines either did not report on PSF or, when reported, their
recommendations were supported by little or low level of evidence.
: Although we identified a number of recent studies which haveConclusion
added to our current knowledge on PSF, none are robust enough to change
current clinical practice.
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Introduction
Post-stroke fatigue (PSF) has been defined as ‘overwhelming 
feeling of exhaustion or tiredness’, which is unrelated to exer-
tion, and does not typically improve with rest1. It is one of the 
most common outcomes of stroke and its prevalence varies 
between 25% and 85%; however, it is generally accepted 
that it affects 50% of people after stroke2. PSF is linked to 
undesirable stroke outcomes and affects patients’ participa-
tion in studies, adherence to medication, and effectiveness of 
rehabilitation3. This has a negative impact on patients’ quality of 
life and daily life activities4–7, and also contributes to the burden 
on family members and carers8.
Although researchers have attempted to explain PSF 
mechanisms9, its aetiology still remains unclear. This is partly 
because there are many contributing factors to PSF8,10–32, and 
each research team may focus only on some of the factors to 
find a route for preventing, treating or managing PSF. Any 
endeavour to find the most effective intervention in the research 
literature leads to a collection of heterogeneous interventions 
from physiotherapy33 and exercise34–38 to psychotherapy, 
pharmacotherapy, and recently laser therapy39–41.
As a systematic effort to review these scattered interventions, 
a Cochrane review42,43 compared all the tested PSF treatments 
to a control group, to standard care, or to each other, through 
reviewing randomised controlled trials (RCTs). This review 
concluded that there was insufficient evidence of the efficacy 
of the tested interventions in trials, and more robust research 
with adequate sample sizes was required42,43. Since then, more 
recent systematic reviews until 2019 have attempted to sum-
marise the evidence of effectiveness of modafinil, mindfulness 
training, a traditional Chinese medicine, and smart technologies, 
but still came toa similar conclusion tothat of the Cochrane review 
in 201544–47.
As a result of such uncertainty, current clinical practice guide-
lines rely on low levels of evidence, such as expert consensus, 
to make recommendations for PSF48,49. However, the efforts 
to design and test treatments continue, which makes it necessary 
to keep up-to-date with new research and practice literature.
Objective
The objective of this review was to identify and summarise 
the most recent research literature related to PSF in order to 
update the evidence base. As there was an existing review 
covering the literature up until 201650, we only updated the 
literature not covered in this review.
Methods
Following methods from an existing review
In 2017, Hinkle et al.50 published a review covering emerg-
ing evidence relating to the management of PSF, up to and 
including February 2016. Because of the comprehensiveness 
of this review, we only searched for literature published after 
1st March 2016. As the search methods of the Hinkle et al. review 
were not reproducible, and the search strategies and results 
were not available, we contacted the corresponding author and 
their librarian on 15th October 2019. Since we did not receive a 
reply, we designed the search methods for the reported data-
bases in order to capture the majority of the literature included 
in Hinkle et al.’s review.
Following scoping review methods
We followed Arksey and O’Malley framework51 for conduct-
ing this scoping review. We also used Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses-Extension 
for Scoping Reviews(PRISMA-ScR) for reporting52. The 
relevant PRSIMA-ScR checklist is available as Extended data 
and the flow diagram is reported in the Results section 
(Figure 1).
Search methods
We ran a search to include literature between 1st March 
2016 and 19th January 2020 (search date) in CINAHL via 
EBSCOhost, MEDLINE via Ovid SP, PubMed (excluding 
MEDLINE), and PsycINFO via Ovid. There were no limita-
tions to language, document type (e.g., thesis), study completion 
status (e.g., ongoing), and publication status (e.g., unpublished) 
at the search stage. We report the search strategies for all databases 
in Extended data.
Selection of studies
We imported the search results into EndNote X6 and 
de-duplicated them based on title, and additionally double-
checked the automatically identified duplicates manually. Two 
reviewers (GA and FS) screened the results independently against 
the eligibility criteria using Rayyan, which is a recommended 
screening system53. Discrepancies were resolved through 
discussions or asking a third reviewer (AD).
Two reviewers (GA and FS) also investigated the full texts 
of relevant search results against the same criteria involv-
ing a third reviewer (AD) in case of disagreement. At full 
text screening stage, we also investigated the reference lists 
of the relevant studies to identify additional relevant studies. 
Since one study may have multiple reports or publications, 
we kept a record and cited all the reports of a single study 
to provide a better overview of the new research evidence.
Eligibility criteria
We included the following studies: 
-    Studies of adult humans with PSF – any definition 
of PSF – at any stage of the stroke care continuum;
-    Any interventional (clinical trial) or observational 
(cohort, case-control, and cross-sectional) studies, and 
clinical practice guidelines;
-    Studies reporting findings that had not been included 
in the previous review;
-    Studies included in relevant systematic reviews.
We excluded the following studies: 
-    Studies with case reports, case series, and qualitative 
design;
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-    Studies included in Hinkle et al. or results which 
repeated the summarised knowledge in that review;
-    Studies of pre-clinical nature;
-    Clinical studies where fatigue was reported only as a side 
effect of the treatment;
-    Studies focusing on single muscle fatigue or muscle 
fatigue in general;
-    Studies not focusing on fatigue and/or stroke or focusing 
on heat stroke, athletes’ fatigue or carers’ fatigue;
-    Systematic or narrative or review papers;
-    Ongoing studies or protocols with no results (listed and 
cited in this paper for further follow-up);
-    Tool validation studies without reporting new findings 
on PSF.
Data extraction methods
One reviewer (GA) extracted and entered the data in Excel 
2007 and the second reviewer (FS) checked the extracted 
and entered data against the full text and, if appropriate, 
corrected or amended the data.
For interventional studies, we extracted PICOS (participants, 
intervention, comparison, outcomes, and study design) and 
other data points: 
-    Study name and year;
-    Clinical trial registration number (for further check on 
selective reporting bias);
Figure 1. PRISMA flow diagram.
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-    Country of origin;
-    Number of centres;
-    Patients: Number of patients, type of stroke, time passed 
after stroke;
-    Intervention and controls: name of intervention and 
duration;
-    Primary and secondary outcomes measures in general 
and fatigue measures in particular, outcome endpoints, 
and main findings related to PSF;
-    Study design (single-arm clinical trial (CT), controlled 
clinical trial (CCT), or RCT);
For observational studies, we extracted: 
-    Study name and year;
-    Clinical trial registration number (for further check on 
selective reporting bias);
-    Country of origin;
-    Number of centres;
-    Patients: Number of patients, type of stroke, time passed 
after stroke;
-    Primary and secondary outcomes measures in general 
and fatigue measures in particular, outcome endpoints, 
and main findings related to PSF;
-    Study design (cohort, case-control, or cross-sectional).
For clinical practice guidelines, we extracted the following data: 
-    Study name and year;
-    Country and organisation who produced the guideline;
-    Recommendations on PSF;
-    Evidence base reporting the level of evidence or 
study designs related to the level of evidence.
Quality assessment methods
We used RobotReviewer for assessing the risk of bias in the 
four categories of the Cochrane Risk of Bias tool54 for included 
RCTs. Although this automation system is reliable for check-
ing the risk of bias for certain bias categories55,56, one of the 
reviewers (GA) also double-checked and revised RobotReview-
er’s assessment and corrected the data where necessary. We 
also added a ‘selective reporting of outcomes’ category to 
the list of biases to cover the main biases in Cochrane Risk of Bias 
tool.
Synthesis methods
We summarised the data from the new relevant literature in tables. 
We did not proceed to a meta-analysis for fatigue outcomes due 
to the heterogeneity of studies. We checked if any of the inter-
ventional studies considered following the CONSORT57 for 
reporting RCTs or TIDieR checklist58 to report the components 
of new interventions.
Results
The search identified 1021 results. After screening, we included 
45 relevant records related to 24 studies and 6 guidelines 
(Figure 1).
The characteristics of included interventional studies have 
been charted in Table 1. The table shows eight RCTs some 
with multiple reports and one with a follow-up study59–73, one 
CCT74, and two single-arm trials75,76. All studies were based on 
single centre studies, except for West et al. (2019) which 
had two centres71. In studies that reported the intervention 
delivery details, the psychological interventions were delivered 
individually and face-to-face – rather than online – bypsychologists. 
We also assessed the risk of bias for RCTs and reported the 
categories of risk in Table 2 with supporting statements in 
Extended data.
Most of the interventional studies have a medium to high risk 
of bias. Table 2 shows only two studies in green (indicating 
low risk of bias) but both have small sample size consisting of 
34 (MIDAS study63–68) and 64 randomised patients61 respectively.
We identified 14 observational studies of which half had a 
prospective cohort design77–90 and the other half were cross-
sectional surveys91–97. Three cross-sectional surveys were 
embedded within cohort studies91,94,97. Only one of the 
studies (NotFAST) had a follow-up report81–85. Details of all 
studies are reported in Table 3 as well as the Extended data.
Table 4 summarises the main finding of each interventional 
study all of which either have high risk of bias or small sample 
size. Such limitations make it hard to transfer the research 
findings to practice.
The majority of observational studies investigated factors 
related to PSF including co-morbidities, physical and mental 
outcomes, illness characteristics, characteristics of interventions, 
and biomarkers (Table 5).
We identified six recent guidelines from three English-speaking 
countries including the UK49 and two North American coun-
tries (one from Canada48 and four from the USA98–101). Among 
these, the Canadian guideline was the most recent and the 
only one with comprehensive recommendations on PSF. 
The UK guideline will be updated in 2021. Half of these guide-
lines, that is, all those from USA, have not provided specific 
recommendations on PSF, as reported in Table 6. In almost all 
the guidelines, the reliance on ‘experts’ consensus’ is apparent 
because of the limited evidence base for PSF (Table 6).
Discussion
We conducted this review to identify and summarise the most 
recent research studies on PSF since Hinkle et al.’s review 
(2017)50. We therefore documented the interventional and 
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Table 3. Characteristics of included observational studies.
Study name Country # of 
centres Design
# 
participants Stroke type
Time after 
stroke
ARCOS-IV New Zealand 4 Cross-
Sectional 
(in 
Cohort)
256/2096* First/Ischemic/Haemorrhagic/Undetermined 4 Y
Blomgren et al. 
2019
Sweden 1 Cohort 296/411 First/Recurrent/Ischemic 7 Y
Chen et al. 2018 USA 1 Cohort 128/203 Ischemic/Haemorrhagic 6 M
Choi-Kwon et al. 
2017a
South Korea 1 Cross-
Sectional
373/469 Ischemic 3 M
Choi-Kwon et al. 
2017b
South Korea 1 Cohort 364/508 Ischemic 12 M
Douven et al. 2017 Netherlands 2 Cohort 243/250 First/Ischemic 3, 6, 12 M
Kuppuswamy  
et al. 2016
UK 3 Cross-
Sectional
69 First 56.81±63 M
LAS-1 Sweden 1 Cross-
Sectional 
(in 
Cohort)
349 NR 6 Y
Table 2. Risk of bias assessed by RobotReviewer 
and a human reviewer for randomised controlled 
trials.
Trial
R
andom
 sequence g
en
eration
A
llocation concealm
ent
B
linding of participants and perso
n
n
el
B
linding of outcom
e assessm
ent
Selective reporting of outcom
es
Chen et al. 2016 ? ? ? + +
Chen et al. 2019 + + ? ? ?
Delva 2019 ? ? ? ? ?
Liu et al. 2016 + + + + +
Liu et al. 2018 ? ? ? ? ?
MIDAS + + + + +
Nguyen et al. 2019 + + ? + ?
West et al. 2019 + + ? ? +
Question marks in red cells indicate unclear or high risk of bias 
and plus signs in green cells show low risk of bias.
observational research and clinical practice guidelines since March 
2016. However, there were some key contributors to the weak 
evidence base: (i) recording and reporting only some 
contributing factors to PSF in observational studies, (ii) the het-
erogeneity of designed interventions, (iii) high risk of bias, 
(iv) small sample size in interventional studies, and (v) variety 
of outcome measures in both observational and clinical studies. 
This, in turn, is reflected in the quality of the clinical 
recommendations for PSF.
Despite the high prevalence of PSF2 and its obvious effects on 
treatment adherence102, in practice, only half of recent stroke 
guidelines have clinical recommendations on PSF. Of those that 
do, two guidelines provide only brief recommendations, and 
only one provides comprehensive recommendations, but these 
are based on low levels of evidence48. The weak evidence base 
and the need to rely on expert consensus is likely to be the 
main reason that PSF is generally not covered in the guidelines.
The dominance of single-centred interventional studies with 
small sample sizes and interventions delivered within a 12-week 
period may be the reasons for absence of follow-up studies. 
MIDAS (interventional)63–65 and NotFAST (observational)81–85 
are the only recent studies with novel and potentially long-
term findings with larger sample size (in case of MIDAS 2)103 or 
with the intention to design an intervention (NotFAST2)104.
While the observational studies reported the type of stroke, the 
interventional studies did not include this important data, which 
makes it difficult to summarise studies. Most of participants 
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Table 4. Descriptive summary of findings from included interventional studies.
Study Name Fatigue 
measure
Endpoint Main PSF finding*
Chen et al. 2016 Secondary: FAS W 10 There were no significant changes from baseline in FAS in either group.
Chen et al. 2019 Fatigue VAS D 5, 10 Fatigue was not significantly associated with change in quality of life and was not 
different in two groups.
Delva 2019 FAS D 3, M 1, 3 The use of aspirin in high dose during 3 months with PSF diagnosis within the first 
days post-stroke is associated with decreasing of fatigue intensity due to FAS and 
modifying of post-stroke inflammatory response.
Liu et al. 2016 Primary: BFI D28±5, 
84±5
Astragalus membranaceus group had improved fatigue post-therapy and in follow-
up.
Liu et al. 2018 Barthel Index W 12 Wuling can inhibit the release rate of inflammatory factor, reduce the expression 
level of related inflammatory factors and improve PSF.
MIDAS Primary: MFI W 6, 7 Modafinil group reported decrease in fatigue and improvement in quality of life.
M 12 MFI and quality of life at baseline and their changes during treatment were 
correlated. Five of the patients who continued taking daily modafinil demonstrated 
sustained improvement in MFI compared to baseline.
Nguyen et al. 2019 Primary: FSS M 2, 4 CBT group demonstrated reduced fatigue relative to TAU. CBT gains were 
maintained for two months post-therapy.
Van Heest et al. 
2017
Primary: FACIT-
Fatigue
W 6, 12 Participants showed reductions in fatigue at post-test and maintained it at follow-
up.
West et al. 2019 Primary: MFI Discharge At discharge, patients from the naturalistic light group experienced less fatigue 
than the indoor light group.
Wu et al. 2017 Secondary: FAS S 6, 1, M 3 This psychological intervention was acceptable to stroke patients and was feasible 
in the local health service.
FAS: Fatigue Assessment Scale; VAS: Visual Analogue Scale; BFI: Brief Fatigue Index; MFI: Multidimensional Fatigue Inventory; FSS: Fatigue Severity Scale; 
FACIT: Functional Assessment of Chronic Illness Therapy; W: Weeks; D: Day; M: Month; S: Session; TAU: Treatment As Usual; CBT: Cognitive Behavioural 
Therapy.
* Grey cells contain findings from low risk studies;however they have small sample size.
White cells report findings from studies with high or unclear risk of bias.
Study name Country # of 
centres Design
# 
participants Stroke type
Time after 
stroke
Lau et al. 2017 Hong Kong 1 Cross-
Sectional
191 Ischemic 3 M
MacIntosh  
et al. 2017
Canada 4 Cross-
Sectional
335 Ischemic/Haemorrhagic Within 6 M
NotFAST UK 4 Cohort 268/371 First 4-6 W
Follow-
Up
263/371 6 M
STROKDEM France 4 Cohort 153/179 Ischemic/Haemorrhagic 6 M
van Rijsbergen  
et al. 2019
Netherlands 1 Cross-
Sectional 
(in 
Cohort)
208 First/Ischemic/Haemorrhagic/Recurrent 3.3±0.5 M
Wang et al. 2018 China 1 Cohort 634/703 Ischemic Within 3 D
NR: Not Reported; Y: Year; M: Month; W: Week; D: Day
*For cohort studies, the left number shows the number of participants who finished follow-up, and the right number is the number of participants who started 
and took part in the study; for cross-sectional studies within cohort studies, the left number shows the number of participants in cross-sectional study and the 
right number is the number of participants in cohort study.
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Table 5. Descriptive summary of findings from included observational studies.
Study name Fatigue 
measure
Finding
ARCOS-IV FSS Having hypertension, diabetes mellitus, and arrhythmia at the time of stroke were associated 
with increased PSF.
Blomgren et al. 
2019
FIS Fatigue was independently explanatory of worse outcome on FAI summary score and domestic 
chores.
Chen et al. 2018 FACIT-
Fatigue
Early PSF appears to be largely attributable to stroke severity, while chronic fatigue occurs in 
the setting of medical co-morbidities and medication use.
Choi-Kwon et al. 
2017a
FSS Of the 6 polymorphisms examined, only one marker, that is, low-activity Monoamine Oxidase A 
was associated with PSF in female patients.
Choi-Kwon et al. 
2017b
FSS Musculoskeletal pain and central post-stroke pain was related to fatigue.
Douven et al. 2017 FSS No association between apathy and fatigue was found at baseline and no interaction with time 
was found. Change in fatigue from baseline to 12-month follow-up was associated with change 
in depression and with change in apathy. Bidirectional associations were found between PSF 
and PSD.
Kuppuswamy et al. 
2016
FSS Those with high perceived limb heaviness also reported significantly higher levels of fatigue 
than those with no perceived limb heaviness, but there was no difference in weakness between 
the 2 groups.
LAS-1 FSS In almost all Stroke Impact Scale domains the odds for PSF were higher in persons with a higher 
perceived impact. Fatigue is still present in one-third of persons six years after stroke onset.
Lau et al. 2017 FAS Fatigue severity positively correlated with NEO Five-Factor Inventory neuroticism scores.
MacIntosh et al. 
2017
FAS Fatigue and depressive symptoms are related distinctly to cognitive and mobility impairments 
post-stroke. Fatigue was associated with poorer lower limb motor function, and with cognition 
indirectly via depressive symptoms.
NotFAST FSS of FAI Pre-stroke fatigue, having a spouse/partner, lower Rivermead Mobility Index score, and higher 
scores on both the Brief Assessment Schedule Depression Cards and Beck Anxiety Index 
were independently associated with PSF.Of those reporting fatigue initially 69% continued to 
report fatigue in follow-up. New PSF cases were reported by 38%. Lower Nottingham Extended 
Activities of Daily Living scores and higher Beck Anxiety Index scores were independently 
associated with fatigue at six months.
STROKDEM CFS Medication use was not a PSF predictor; however, polypharmacy increased PSF severity.
van Rijsbergen  
et al. 2019
FAS Fatigue was associated with CLCE scores, independent of demographic, cognitive 
performance and stroke-related covariates. After including personality traits and coping 
styles in the model, independent associations with CLCE scores were found for fatigue and 
neuroticism.
Wang et al. 2018 FSS The serum levels of thyroid-stimulating hormone were inversely associated with the risk of PSF 
in both the acute phase and at follow-up. Thyroid function profiles may be predictor of PSF after 
acute ischemic stroke.
FSS: Fatigue Severity Scale; FIS: Fatigue Impact Scale; FACIT: Functional Assessment of Chronic Illness Therapy; FAS: Fatigue Assessment Scale;  
FAI: Fatigue Assessment Inventory; PSD: Post-Stroke Depression; CFS: Chalder Fatigue Scale; CLCE: Checklist for Cognitive and Emotional 
consequences following stroke
entered the interventional studies three-months after stroke. 
This is likely to be due to a number of reasons; for example, 
fatigue is not recognised immediately after a stroke, some stud-
ies want to ensure that participants have a stabile fatigue, and 
there is competition for recruitment in the early stages to more 
acute trials.
The variety of the interventions tested in studies and 
trials underlines the complexity of PSF and is an indication to 
researchers that probably the most effective interventions need 
to target multiple aspects of fatigue. While current reporting 
practice of interventions in RCTs included in our review is of 
concern (none followed TIDieR and two followed CONSORT), 
future studies should consider following reporting guidelines 
such as CONSORT and TIDieR for interventional studies, 
STROBE for observational studies, and RIGHT105, AGREE106, or 
CheckUP107 for clinical practice guidelines.
Among the observational studies, the populations-based 
study from the stroke register in New Zealand91 and Sweden77 
provides valuable insights about the link between co-morbidities 
and increased PSF in long-term (4–7 years). This, and other 
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similar register-based studies, represent the added value of having 
high-quality data in health system databases for long-term 
observational and register-based studies108.
Psychologists delivered the psychotherapies in RCTs to 
individual patients and there was no intervention using online 
platforms as the media of delivery. This may be due to a number 
of reasons: it is usual to test the efficacy of an intervention 
face to face before moving to another medium; participants 
with stroke may have other problems which mean it is more 
difficult to deliver treatments online, e.g. communication issue 
and cognitive problems.
Fatigue Severity Scale (FSS) was the main outcome measure 
for PSF in observational studies, whereas Fatigue Assessment 
Scale (FAS)was used more frequently than other measures 
in interventional studies. The main reason that the FSS has 
been used is probably because it is now seen as a way to 
compare different studies: in simple terms, researchers use 
it because other researchers have used it. It is also relatively 
straight forward to complete.
Only one of observational studies and half of the interventional 
studies were registered in clinical trial registers, with the remaining 
unregistered trials potentially introducing bias in selective 
reporting of outcomes109,110. One of the interventional studies 
was registered retrospectively with potential for the same bias69,70.
Limitations
It is possible that we overlooked studies which did not report 
PSF in the searchable part of the paper or if the report was 
not indexed in the searched databases. In such cases, we invite 
the audience of this review paper to contact us or comment 
on the paper online.
Conclusion
The current trend of research on PSF shows the contin-
ued importance of this topic globally. Our review identified a 
weak evidence base that highlights the need for more research 
that could have the following characteristics: I) studies to 
design and test multi-component interventions for PSF; and 
II) Robust RCTs with adequate sample sizes to produce the 
evidence for recommendations in guidelines. From our current 
knowledge on PSF, none of the recent studies are robust enough 
to change current clinical practice.
Data availability
Underlying data
Open Science Framework: Post-Stroke Fatigue: A Scoping Review, 
https://doi.org/10.17605/OSF.IO/XJKCS111.
Table 6. Descriptive summary of included clinical practice guidelines.
Citation Country-
Organisation
Recommendation Evidence base
Braun et al. 
2016
USA-AHA/ASA None NR
Lanctot et al. 
2019
Canada-CSBPR See pages 15–16 of guideline. RCT, CCT, CT, 
Consensus
NICE 2017 UK-NICE Assess the person for mental and physical factors that may contribute to fatigue. 
Treat any reversible causes or exacerbating factors. Provide the person and their 
family/carers with information and help in anticipating and managing fatigue such 
as daily routines, modified tasks which balance activity and rest, planned exercise 
schedules, and sleep hygiene.
Cochrane SR, 
SR, Consensus
Peberdy et al. 
2017
USA-AHA None NR
VA-DoD 2019 USA-VA/DoD None NR
Winstein et al. 
2016
USA-AHA/ASA An RCT compared a multi-component cognitive therapy + graded activity training 
versus cognitive therapy for 12 weeks and showed that the multi-component 
therapy is better than the cognitive therapy in reducing fatigue and improving 
physical endurance … myths about exercise being unsafe, causing another 
stroke, or increasing fatigue should be dispelled during rehabilitation … evidence 
is limited, many clinicians advise that for individuals who want to return to work, a 
tailored assessment of cognitive, perception, physical, and motor abilities can be 
performed to determine readiness and the needed accommodations to return to 
work based on individual’s needs and capabilities for the specified job situation. 
The assessment may include executive functions, high-level oral and written 
communication, and fatigue. Once performance under the best conditions has 
been assessed, further assessment under conditions of fatigue and stress may be 
useful to mimic potential job situations.
RCT
AHA: American Heart Association; ASA: American Stroke Association; VA/DoD: Department of Veterans Affairs/Department of Defense; NICE: National Institute 
for Health and Care Excellence; CSBPR: Canadian Stroke Best Practice Recommendations by Management of Mood, Cognition and Fatigue Following Stroke 
Best Practice Writing Group/Heart & Stroke Canadian Stroke Best Practices and Quality Advisory Committee/Canadian Stroke Consortium; NR: Not Reported; 
RCT: Randomised Controlled Trial; CCT: Controlled Clinical Trial; CT: Clinical Trial; SR: Systematic Review.
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Registration DOI: https://doi.org/10.17605/OSF.IO/XJKCS
This project contains the following underlying data: 
-    Extracted data from included studies
Extended data
Open Science Framework: Post-Stroke Fatigue: A Scoping Review, 
https://doi.org/10.17605/OSF.IO/XJKCS111.
This project contains the following extended data: 
-    Full search strategies
-    Risk of bias assessment
Unedited draft of risk of bias reported by 
RobotReviewer: https://robotreviewer.vortext.systems/#report/_
gk5JV8oLUAd9lhmsx71G
Reporting guidelines
Open Science Framework: PRISMA-ScR checklist for 
‘Post-stroke fatigue: a scoping review’, https://doi.org/10.17605/
OSF.IO/XJKCS111.
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
References
1. De Groot MH, Phillips SJ, Eskes GA: Fatigue associated with stroke and other 
neurologic conditions: Implications for stroke rehabilitation. Arch Phys Med 
Rehabil. 2003; 84(11): 1714–20.  
PubMed Abstract | Publisher Full Text 
2. Cumming TB, Packer M, Kramer SF, et al.: The prevalence of fatigue after stroke: 
A systematic review and meta-analysis. Int J Stroke. 2016; 11(9): 968–77. 
PubMed Abstract | Publisher Full Text 
3. ACTRN12619000826145: Too tired to recover: evaluation of a post-stroke 
fatigue management guideline. 2019.  
Reference Source
4. Lerdal A, Gay CL: Acute-Phase Fatigue Predicts Limitations with Activities of 
Daily Living 18 Months after First-Ever Stroke. J Stroke Cerebrovasc Dis. 2017; 
26(3): 523–31.  
PubMed Abstract | Publisher Full Text 
5. Ramírez-Moreno JM, Munoz-Vega P, Alberca SB, et al.: Health-Related Quality 
of Life and Fatigue After Transient Ischemic Attack and Minor Stroke. J Stroke 
Cerebrovasc Dis. 2019; 28(2): 276–84.  
PubMed Abstract | Publisher Full Text 
6. Toy G, Singer J, Balucani C, et al.: Post Stroke Fatigue and Depression Predict 
Lower Health Related Quality of Life in Stroke Patients. Stroke (00392499). 
2017; 48: ATP153–ATP.  
Reference Source
7. Broussy S, Saillour-Glenisson F, Garcia-Lorenzo B, et al.: Sequelae and Quality of 
Life in Patients Living at Home 1 Year After a Stroke Managed in Stroke Units. 
Front Neurol. 2019; 10: 907.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. Mandliya A, Das A, Unnikrishnan JP, et al.: Post-stroke Fatigue is an Independent 
Predictor of Post-stroke Disability and Burden of Care: A Path analysis Study. 
Top Stroke Rehabil. 2016; 23(1): 1–7.  
PubMed Abstract | Publisher Full Text 
9. De Doncker W, Dantzer R, Ormstad H, et al.: Mechanisms of poststroke fatigue. 
J Neurol Neurosurg Psychiatry. 2018; 89(3): 287–93.  
PubMed Abstract | Publisher Full Text 
10. Paciaroni M, Acciarresi M: Poststroke Fatigue. Stroke. 2019; 50(7): 1927–33. 
PubMed Abstract | Publisher Full Text 
11. Aarnes R, Stubberud J, Lerdal A: A literature review of factors associated 
with fatigue after stroke and a proposal for a framework for clinical utility. 
Neuropsychol Rehabil. 2019; 1–28.  
PubMed Abstract | Publisher Full Text 
12. Cumming TB, Yeo AB, Marquez J, et al.: Investigating post-stroke fatigue: An 
individual participant data meta-analysis. J Psychosom Res. 2018; 113: 107–12. 
PubMed Abstract | Publisher Full Text 
13. Delva II, Delva MY, Poltorapavlov VA: Clinical factors related to post-stroke 
fatigue within the first 3 month after acute cerebrovascular events. Wiad Lek. 
2017; 70(3 pt 2): 581–5.  
PubMed Abstract 
14. Delva II, Lytvynenko NV, Delva MY: Post-stroke fatigue and its dimensions 
within first 3 months after stroke. Wiad Lek. 2017; 70(1): 43–6.  
PubMed Abstract 
15. Delva I: Factors associated with post-stroke fatigue dimensions over the 
second year after acute cerebrovascular events. Bulletin of Problems Biology 
and Medicine. 2018; 42(2 (147)): 139–42.  
Publisher Full Text 
16. Delva I, Lytvynenko N, Delva M: Factors Associated with Post-Stroke Fatigue 
within the First 3 Month after Stroke. Georgian Med News. 2017; 2017(6 (267)): 
38–42.  
PubMed Abstract 
17. Delva M, Lytvynenko N, Delva I: Factors Associated with Post-Stroke Fatigue 
during the Second Half Year after Stroke. Georgian Med News. 2017;  
2017(11 (272)): 59–64.  
PubMed Abstract 
18. Delva M, Lytvynenko N, Delva I: Factors Associated with the Time-Based 
Phenomenology of Post-Stroke Fatigue over the First Year after Stroke 
Occurrence. Georgian Med News. 2018; 2018(6 (279)): 92–7.  
PubMed Abstract 
19. Delva MY, Delva II, Lytvynenko NV: Post-stroke fatigue and its dimensions over 
the second half year after stroke. Wiad Lek. 2018; 71(2 pt 2): 314–7.  
PubMed Abstract 
20. Galligan NG, Hevey D, Coen RF, et al.: Clarifying the associations between 
anxiety, depression and fatigue following stroke. J Health Psychol. 2016; 21(12): 
2863–71.  
PubMed Abstract | Publisher Full Text 
21. Goh HT, Stewart JC: Poststroke Fatigue Is Related to Motor and Cognitive 
Performance: A Secondary Analysis. J Neurol Phys Ther. 2019; 43(4): 233–9.   
PubMed Abstract | Publisher Full Text 
22. Graber M, Garnier L, Duloquin G, et al.: Association Between Fatigue and 
Cognitive Impairment at 6 Months in Patients With Ischemic Stroke Treated 
With Acute Revascularization Therapy. Front Neurol. 2019; 10: 931.  
PubMed Abstract | Publisher Full Text | Free Full Text 
23. Holmqvist A, Berthold Lindstedt M, Möller MC: Relationship between fatigue after 
acquired brain injury and depression, injury localization and aetiology: an 
explorative study in a rehabilitation setting. J Rehabil Med. 2018; 50(8): 725–31.  
PubMed Abstract | Publisher Full Text 
24. Khan A, Delargy M: Post Stroke Fatigue; Point Prevalence, Characterization, 
Associations and Radiological Correlation in a Rehabilitation Hospital. Ir Med 
J. 2017; 110(10): 650.  
PubMed Abstract 
25. Lagogianni C, Thomas S, Lincoln N: Examining the relationship between fatigue 
and cognition after stroke: A systematic review. Neuropsychol Rehabil. 2018; 
28(1): 57–116.   
PubMed Abstract | Publisher Full Text 
26. Liu X: Fatigue and depression in Chinese stroke patients: A 1-year longitudinal 
study. Dissertation Abstracts International: Section B: The Sciences and 
Engineering. 2018; 79(1).
27. Murphy S, Durand M, Negro F, et al.: The Relationship Between Blood Flow and 
Motor Unit Firing Rates in Response to Fatiguing Exercise Post-stroke. Front 
Physiol. 2019; 10: 545.  
PubMed Abstract | Publisher Full Text | Free Full Text 
28. Mutai H, Furukawa T, Houri A, et al.: Factors associated with multidimensional 
aspect of post-stroke fatigue in acute stroke period. Asian J Psychiatr. 2017; 26: 
1–5.  
PubMed Abstract | Publisher Full Text 
29. Sarfo FS, Berchie P, Singh A, et al.: Prevalence, Trajectory, and Predictors of 
Poststroke Fatigue among Ghanaians. J Stroke Cerebrovasc Dis. 2019; 28(5): 
1353–61. Corporate Author: PINGS Study Investigators.   
PubMed Abstract | Publisher Full Text | Free Full Text 
30. Schow T, Teasdale TW, Quas KJ, et al.: Problems with balance and binocular 
visual dysfunction are associated with post-stroke fatigue. Top Stroke Rehabil. 
Page 11 of 14
F1000Research 2020, 9:242 Last updated: 07 APR 2020
2017; 24(1): 41–9.   
PubMed Abstract | Publisher Full Text 
31. Shepherd AI, Pulsford R, Poltawski L, et al.: Physical activity, sleep, and fatigue 
in community dwelling Stroke Survivors. Sci Rep. 2018; 8(1): 7900.  
PubMed Abstract | Publisher Full Text | Free Full Text 
32. Syla D, Sweenie A, Lendrem D, et al.: A scoping exercise to gauge the incidence 
of early post-stroke fatigue for patients at Newcastle community stroke 
services. International Journal of Therapy & Rehabilitation. 2017; 24(2): 52.   
Publisher Full Text 
33. Alahmari W, Alhowimel A, Alotaibi M, et al.: Effectiveness of physiotherapy 
interventions for post stroke fatigue (PSF): a systematic review. Physiotherapy. 
2019; 105(Suppl 1): e172.   
Publisher Full Text 
34. Gbiri CAO, Olawale OA, Ogunmola OT: Task-oriented circuit training for 
post-stroke fatigue, sleeppattern, functional performance and societal re-
integration in stroke survivors with post-stroke fatigue: a clinical controlled 
study. International journal of stroke Conference: 11th world stroke congress, WSC 
2018 Canada. 2018; 13(2 Supplement 1): 86.  
Publisher Full Text 
35. Durand MJ, Boerger TF, Nguyen JN, et al.: Two weeks of ischemic conditioning 
improves walking speed and reduces neuromuscular fatigability in chronic 
stroke survivors. J Appl Physiol (1985). 2019; 126(3): 755–63.  
PubMed Abstract | Publisher Full Text | Free Full Text 
36. Durand MJ, Murphy SA, Schmit BD, et al.: Two Weeks of Ischemic 
Preconditioning Training on the Paretic Leg Improves Leg Strength and Delays 
Muscle Fatigue in Chronic Stroke. Stroke. 2017; 48: ATP150–ATP.  
Reference Source
37. Shahar N, Schwartz I, Portnoy S: Differences in muscle activity and fatigue of 
the upper limb between Task-Specific training and robot assisted training 
among individuals post stroke. J Biomech. 2019; 89: 28–33.  
PubMed Abstract | Publisher Full Text 
38. Vecchio M, Gracies JM, Panza F, et al.: Change in Coefficient of Fatigability 
Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: 
a Prospective Open-Label Observational Study. J Stroke Cerebrovasc Dis. 2017; 
26(11): 2536–40.  
PubMed Abstract | Publisher Full Text 
39. da Silva BP, Souza GADS, Filho AADN, et al.: Analysis of the effects of low-
level laser therapy on muscle fatigue of the biceps brachii muscle of healthy 
individuals and spastic individuals: Study protocol for a single-center, 
randomized, double-blind, and controlled clinical trial. Medicine (Baltimore). 
2019; 98(39): e17166.  
PubMed Abstract | Publisher Full Text | Free Full Text 
40. das Neves M, Reis M, Andrade E, et al.: Effects of low-level laser therapy (LLLT 
808 nm) on lower limb spastic muscle activity in chronic stroke patients. 
Lasers Med Sci. 2016; 31(7): 1293–300.   
PubMed Abstract | Publisher Full Text 
41. das Neves MF, Aleixo DC, Mendes IS, et al.: Long-term analyses of spastic 
muscle behavior in chronic poststroke patients after near-infrared low-level 
laser therapy (808 nm): a double-blinded placebo-controlled clinical trial. 
Lasers Med Sci. 2019.  
PubMed Abstract | Publisher Full Text 
42. Kennedy C, Kidd L: Interventions for post-stroke fatigue: A Cochrane review 
summary. Int J Nurs Stud. 2018; 85: 136–137.  
PubMed Abstract | Publisher Full Text 
43. Wu S, Kutlubaev MA, Chun HY, et al.: Interventions for post-stroke fatigue. 
Cochrane Database Syst Rev. 2015; (7): CD007030.  
PubMed Abstract | Publisher Full Text 
44. Xu L, Xu XY, Hou XQ, et al.: Adjuvant therapy with Astragalus membranaceus 
for post-stroke fatigue: a systematic review. Metab Brain Dis. 2020; 35(1): 
83–93.  
PubMed Abstract | Publisher Full Text 
45. Kettlewell J, das Nair R, Radford K: A systematic review of personal smart 
technologies used to improve outcomes in adults with acquired brain injuries. 
Clin Rehabil. 2019; 33(11): 1705–1712.  
PubMed Abstract | Publisher Full Text 
46. Ulrichsen KM, Kaufmann T, Dorum ES, et al.: Clinical Utility of Mindfulness 
Training in the Treatment of Fatigue After Stroke, Traumatic Brain Injury and 
Multiple Sclerosis: A Systematic Literature Review and Meta-analysis. Front 
Psychol. 2016; 7: 912.  
PubMed Abstract | Publisher Full Text | Free Full Text 
47. Pacheco RL, Latorraca COC, da Silva LDGM, et al.: Modafinil for poststroke 
patients: A systematic review. Int J Clin Pract. 2019; 73(2): e13295.  
PubMed Abstract | Publisher Full Text 
48. Lanctot KL, Lindsay MP, Smith EE, et al.: Canadian Stroke Best Practice 
Recommendations: Mood, Cognition and Fatigue following Stroke, 6th edition 
update 2019. Int J Stroke. 2019; InPress:InPress.  
PubMed Abstract | Publisher Full Text 
49. National Institute for Health and Care Excellence. Stroke and TIA. 2017. 
Reference Source
50. Hinkle JL, Becker KJ, Kim JS, et al.: Poststroke Fatigue: Emerging Evidence 
and Approaches to Management: A Scientific Statement for Healthcare 
Professionals From the American Heart Association. Stroke. 2017; 48(7): e159–e170. 
PubMed Abstract | Publisher Full Text 
51. Arksey H, O'Malley L: Scoping studies: towards a methodological framework. 
Int J Soc Res Methodol. 2005; 8(1): 19–32.  
Publisher Full Text 
52. Tricco AC, Lillie E, Zarin W, et al.: PRISMA Extension for Scoping Reviews 
(PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169(7): 467–73. 
PubMed Abstract | Publisher Full Text 
53. Harrison H, Griffin SJ, Kuhn I, et al.: Software tools to support title and abstract 
screening for systematic reviews in healthcare: an evaluation. BMC Med Res 
Methodol. 2020; 20(1): 7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
54. Higgins JPT, Altman DG: Assessing Risk of Bias in Included Studies.2008; 
187–241.  
Publisher Full Text 
55. Marshall IJ, Kuiper J, Wallace BC: RobotReviewer: evaluation of a system for 
automatically assessing bias in clinical trials. J Am Med Inform Assoc. 2016; 
23(1): 193–201.  
PubMed Abstract | Publisher Full Text | Free Full Text 
56. Gates A, Vandermeer B, Hartling L: Technology-assisted risk of bias 
assessment in systematic reviews: a prospective cross-sectional evaluation 
of the RobotReviewer machine learning tool. J Clin Epidemiol. 2018; 96: 54–62. 
PubMed Abstract | Publisher Full Text 
57. Schulz KF, Altman DG, Moher D, et al.: CONSORT 2010 statement: updated 
guidelines for reporting parallel group randomised trials. BMJ. 2010; 340: c332. 
PubMed Abstract | Publisher Full Text | Free Full Text 
58. Hoffmann TC, Glasziou PP, Boutron I, et al.: Better reporting of interventions: 
template for intervention description and replication (TIDieR) checklist and 
guide. BMJ. 2014; 348: g1687.  
PubMed Abstract | Publisher Full Text 
59. Chen PC, Liaw MY, Wang LY, et al.: Inspiratory muscle training in stroke 
patients with congestive heart failure: A CONSORT-compliant prospective 
randomized single-blind controlled trial. Medicine. 2016; 95(37): e4856.  
PubMed Abstract | Publisher Full Text | Free Full Text 
60. Chen CH, Hung KS, Chung YC, et al.: Mind-body interactive qigong improves 
physical and mental aspects of quality of life in inpatients with stroke: A 
randomized control study. Eur J Cardiovasc Nurs. 2019; 18(8): 658–66.  
PubMed Abstract | Publisher Full Text 
61. Liu CH, Tsai CH, Li TC, et al.: Effects of the traditional Chinese herb Astragalus 
membranaceus in patients with poststroke fatigue: A double-blind, 
randomized, controlled preliminary study. J Ethnopharmacol. 2016; 194:  
954–962.  
PubMed Abstract | Publisher Full Text 
62. Liu F, Li Y, Xu Y: The intervention effect of wuling capsule on inflammatory 
reaction inpatients with post-stroke fatigue. Biomedical Research (India). 2018; 
29(6): 1070–2.  
Publisher Full Text 
63. Bivard A, Lillicrap PT, Krishnamurthy V, et al.: MIDAS (Modafinil in Debilitating 
Fatigue After Stroke): A Randomized, Double-Blind, Placebo-Controlled, 
Cross-Over Trial. Stroke. 2017; 48(5): 1293–1298.  
PubMed Abstract | Publisher Full Text | Free Full Text 
64. Bivard A, Lillicrap T, Krishnamurthy V, et al.: Modafinil In Debilitating fatigue After 
Stroke (MIDAS): a randomized, doubleblind, placebo-controlled, cross-over 
trial. Eur Stroke J. 2017; 2(Suppl 1): 31.  
Publisher Full Text 
65. Lillicrap T, Krishnamurthy V, Attia J, et al.: Modafinil In Debilitating fatigue After 
Stroke (MIDAS): study protocol for a randomised, double-blinded, placebo-
controlled, crossover trial. Trials. 2016; 17(1): 410.  
PubMed Abstract | Publisher Full Text | Free Full Text 
66. Lillicrap TP, Levi CR, Holliday E, et al.: Short- and Long-Term Efficacy of 
Modafinil at Improving Quality of Life in Stroke Survivors: A Post Hoc Sub 
Study of the Modafinil in Debilitating Fatigue After Stroke Trial. Front Neurol. 
2018; 9: 269.  
PubMed Abstract | Publisher Full Text | Free Full Text 
67. Visser MM, Goodin P, Parsons MW, et al.: Modafinil treatment modulates 
functional connectivity in stroke survivors with severe fatigue. Sci Rep. 2019; 
9(1): 9660.  
PubMed Abstract | Publisher Full Text | Free Full Text 
68. Visser MM, Maréchal B, Goodin P, et al.: Predicting Modafinil-Treatment 
Response in Poststroke Fatigue Using Brain Morphometry and Functional 
Connectivity. Stroke. 2019; 50(3): 602–609.  
PubMed Abstract | Publisher Full Text 
69. ACTRN12616001211459. Effectiveness of cognitive behavior therapy for post-
stroke fatigue and sleep disturbance: a pilot randomised controlled trial. 2016. 
Reference Source
70. Nguyen S, Wong D, McKay A, et al.: Cognitive behavioural therapy for post-
stroke fatigue and sleep disturbance: a pilot randomised controlled trial with 
blind assessment. Neuropsychol Rehabil. 2019; 29(5): 723–738.  
PubMed Abstract | Publisher Full Text 
71. West A, Simonsen SA, Jennum P, et al.: An exploratory investigation of 
the effect of naturalistic light on fatigue and subjective sleep quality in 
stroke patients admitted for rehabilitation: A randomized controlled trial. 
NeuroRehabilitation. 2019; 45(2): 187–200.  
PubMed Abstract | Publisher Full Text 
72. West A, Simonsen SA, Jennum PJ, et al.: The effects of circadian light on fatigue 
Page 12 of 14
F1000Research 2020, 9:242 Last updated: 07 APR 2020
and subjective sleep quality in stroke patients admitted for rehabilitation. 
European Stroke Journal. 2017; 2(Suppl 1): 175. 
73. West A, Simonsen SA, Sennels H, et al.: The effect of naturalistic light on 
depressive mood, fatigue, subjective sleep quality and melatonin and cortisol 
blood levels in stroke patients admitted for rehabilitation. Neuropsychobiology. 
2016; 74(4): 255. 
74. Delva II: Effectiveness of acetylsalicylic acid in correction of post-stroke 
fatigue during acute cerebrovascular events. Medical and Ecological Problems. 
2019; 23(1–2): 8–12.  
Publisher Full Text 
75. Van Heest KNL, Mogush AR, Mathiowetz VG: Effects of a One-to-One Fatigue 
Management Course for People With Chronic Conditions and Fatigue. Am J 
Occup Ther. 2017; 71(4): 7104100020p1–7104100020p9.  
PubMed Abstract | Publisher Full Text 
76. Wu S, Chalder T, Anderson KE, et al.: Development of a psychological 
intervention for fatigue after stroke. PLoS One. 2017; 12(8): e0183286.  
PubMed Abstract | Publisher Full Text | Free Full Text 
77. Blomgren C, Samuelsson H, Blomstrand C, et al.: Long-term performance 
of instrumental activities of daily living in young and middle-aged stroke 
survivors-Impact of cognitive dysfunction, emotional problems and fatigue. 
PLoS One. 2019; 14(5): e0216822.  
PubMed Abstract | Publisher Full Text | Free Full Text 
78. Chen K, Marsh EB: Chronic post-stroke fatigue: It may no longer be about the 
stroke itself. Clin Neurol Neurosurg. 2018; 174: 192–197.  
PubMed Abstract | Publisher Full Text 
79. Choi-Kwon S, Ko M, Jun SE, et al.: Post-Stroke Fatigue May Be Associated 
with the Promoter Region of a Monoamine Oxidase A Gene Polymorphism. 
Cerebrovasc Dis. 2017; 43(1–2): 54–58.  
PubMed Abstract | Publisher Full Text 
80. Douven E, Köhler S, Schievink SHJ, et al.: Temporal Associations between 
Fatigue, Depression, and Apathy after Stroke: Results of the Cognition and 
Affect after Stroke, a Prospective Evaluation of Risks Study. Cerebrovasc Dis. 
2017; 44(5–6): 330–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
81. Drummond A, Hawkins L, Sprigg N, et al.: The Nottingham Fatigue after Stroke 
(NotFAST) study: Factors Associated With Severity of Fatigue in Stroke 
Patients Without Depression. Clin Rehabil. 2017; 31(10): 1406–15.  
PubMed Abstract | Publisher Full Text 
82. Hawkins L, Drummond A: Post stroke fatigue: a priority for stroke nursing? Br J 
Neurosci Nurs. 2017; 13(Sup2): S6.  
Publisher Full Text 
83. Hawkins L, Drummond A, Birks E, et al.: The Nottingham Fatigue After Stroke 
study The frequency of fatigue and associated factors in stroke patients 
without depression...The 35th Scientific Meeting of the Physiotherapy 
Research Society 16 April 16, versity of Leicester, UK. International Journal of 
Therapy & Rehabilitation. 2016; 23(6): S270–1. 
84. Hawkins L, Lincoln NB, Sprigg N, et al.: The Nottingham Fatigue After Stroke 
(NotFAST) Study: Results From Follow-Up Six Months After Stroke. Top Stroke 
Rehabil. 2017; 24(8): 592–6.  
PubMed Abstract | Publisher Full Text 
85. Worthington E, Hawkins L, Lincoln N, et al.: The day-to-day experiences of people 
with fatigue after stroke: Results from the Nottingham Fatigue After Stroke 
study. Int J Therapy & Rehabili. 2017; 24(10): 449–55.  
Publisher Full Text 
86. Ponchel A, Labreuche J, Bombois S, et al.: Influence of Medication on Fatigue 
Six Months after Stroke. Stroke Res Treat. 2016: 2410921.  
PubMed Abstract | Publisher Full Text | Free Full Text 
87. Bunevicius A: Reader Response: Depressed TSH Level as a Predictor of 
Poststroke Fatigue in Patients With Acute Ischemic Stroke. Neurology. 2019; 
93(12): 563–4.  
PubMed Abstract | Publisher Full Text 
88. Ganesh A, Galetta S: Editors’ note: Depressed TSH level as a predictor of 
poststroke fatigue in patients with acute ischemic stroke. Neurology. 2019; 
93(12): 563.  
Publisher Full Text 
89. Wang J, Gu M, Sun W, et al.: Author response: Depressed TSH level as a 
predictor of poststroke fatigue in patients with acute ischemic stroke. 
Neurology. 2020.  
Reference Source
90. Wang J, Li F, Xiao L, et al.: Depressed TSH level as a predictor of poststroke 
fatigue in patients with acute ischemic stroke. Neurology. 2018; 91(21):  
e1971–8.  
Publisher Full Text 
91. Mahon S, Theadom A, Barker-Collo S, et al.: The Contribution of Vascular Risk 
Factors in Prevalence of Fatigue Four Years Following Stroke: Results from a 
Population-Based Study. J Stroke Cerebrovasc Dis. 2018; 27(8): 2192–9.  
PubMed Abstract | Publisher Full Text 
92. Choi-Kwon S, Choi SH, Suh M, et al.: Musculoskeletal and central pain at 1 
year post-stroke: associated factors and impact on quality of life. Acta Neurol 
Scand. 2017; 135(4): 419–25.  
PubMed Abstract | Publisher Full Text 
93. Kuppuswamy A, Clark E, Rothwell J, et al.: Limb Heaviness: A Perceptual 
Phenomenon Associated With Poststroke Fatigue? Neurorehabil Neural Repair. 
2016; 30(4): 360–2.  
PubMed Abstract | Publisher Full Text 
94. Elf M, Eriksson G, Johansson S, et al.: Self-Reported Fatigue and Associated 
Factors Six Years after Stroke. PLoS One. 2016; 11(8): e0161942.  
PubMed Abstract | Publisher Full Text | Free Full Text 
95. Lau CG, Tang WK, Liu XX, et al.: Neuroticism and Fatigue 3 Months After 
Ischemic Stroke: A Cross-Sectional Study. Arch Phys Med Rehabil. 2017; 98(4): 
716–21.  
PubMed Abstract | Publisher Full Text 
96. MacIntosh BJ, Edwards JD, Kang M, et al.: Post-stroke Fatigue and Depressive 
Symptoms Are Differentially Related to Mobility and Cognitive Performance. 
Front Aging Neurosci. 2017; 9: 343.  
PubMed Abstract | Publisher Full Text | Free Full Text 
97. van Rijsbergen MWA, Mark RE, Kop WJ, et al.: Psychological factors and 
subjective cognitive complaints after stroke: Beyond depression and anxiety. 
Neuropsychol Rehabil. 2019; 29(10): 1671–84.  
PubMed Abstract | Publisher Full Text 
98. Braun LT, Grady KL, Kutner JS, et al.: Palliative Care and Cardiovascular 
Disease and Stroke: A Policy Statement From the American Heart Association/
American Stroke Association. Circulation. 2016; 134(11): e198–225.  
PubMed Abstract | Publisher Full Text 
99. Peberdy MA, Gluck JA, Ornato JP, et al.: Cardiopulmonary Resuscitation 
in Adults and Children With Mechanical Circulatory Support: A Scientific 
Statement From the American Heart Association. Circulation. 2017; 135(24): 
e1115–34.  
PubMed Abstract | Publisher Full Text 
100. Management of Stroke Rehabilitation Work Group, Office of Quality Safety and 
Value, Office of Evidence Based Practice: VA/DoD Clinical Practice Guideline for 
the Management of Stroke Rehabilitation: Department of Veterans Affairs and 
Department of Defense. 2019.  
Reference Source
101. Winstein CJ, Stein J, Arena R, et al.: Guidelines for Adult Stroke Rehabilitation 
and Recovery: A Guideline for Healthcare Professionals From the American 
Heart Association/American Stroke Association. Stroke. 2016; 47(6): e98–e169. 
PubMed Abstract | Publisher Full Text 
102. Zhang J, Gong Y, Zhao Y, et al.: Post-stroke medication adherence and 
persistence rates: a meta-analysis of observational studies. J Neurol. 2019. 
PubMed Abstract | Publisher Full Text 
103. ACTRN12618000602224: Modafinil In Debilitating Fatigue After Stroke 2 
(MIDAS 2). 2018.  
Reference Source
104. Drummond A: NotFAST2 - Nottingham Fatigue study: developing a fatigue 
intervention. Stroke Association and University of Nottingham. 2019.  
Reference Source
105. Chen Y, Yang K, Marušic A, et al.: A Reporting Tool for Practice Guidelines 
in Health Care: The RIGHT Statement. Ann Intern Med. 2017; 166(2): 128–32. 
PubMed Abstract | Publisher Full Text 
106. Brouwers MC, Kerkvliet K, Spithoff K, et al.: The AGREE Reporting Checklist: a 
tool to improve reporting of clinical practice guidelines. BMJ. 2016; 352: i1152. 
PubMed Abstract | Publisher Full Text | Free Full Text 
107. Vernooij RW, Alonso-Coello P, Brouwers M, et al.: Reporting Items for Updated 
Clinical Guidelines: Checklist for the Reporting of Updated Guidelines 
(CheckUp). PLoS Med. 2017; 14(1): e1002207.  
PubMed Abstract | Publisher Full Text | Free Full Text 
108. Abildstrom SZ, Torp-Pedersen C, Madsen M: Register-based studies of 
cardiovascular disease. Scand J Public Health. 2011; 39(7 Suppl): 165–9. 
PubMed Abstract | Publisher Full Text 
109. Jones CW, Keil LG, Holland WC, et al.: Comparison of registered and published 
outcomes in randomized controlled trials: a systematic review. BMC Med. 
2015; 13: 282.  
PubMed Abstract | Publisher Full Text | Free Full Text 
110. Mathieu S, Boutron I, Moher D, et al.: Comparison of registered and published 
primary outcomes in randomized controlled trials. JAMA. 2009; 302(9): 977–84. 
PubMed Abstract | Publisher Full Text 
111. Shokraneh F, Aali G: Post-Stroke Fatigue: A Scoping Review. 2020.  
http://www.doi.org/10.17605/OSF.IO/XJKCS
Page 13 of 14
F1000Research 2020, 9:242 Last updated: 07 APR 2020
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact  research@f1000.com
Page 14 of 14
F1000Research 2020, 9:242 Last updated: 07 APR 2020
